Paul Hemings, Nelson Advisors: Corporate Finance Foundations, Entrepreneurial Operations and Venture Exits

Nelson Advisors
1 hour ago
12 min read

Executive Summary and Professional Profile

The global mergers and acquisitions (M&A) landscape within Healthcare Technology (HealthTech), Medical Technology (MedTech), Digital Health, Healthcare IT, and Healthcare Artificial Intelligence (AI) has undergone a fundamental structural transformation. Driven by macroeconomic realignments, regulatory complexities, and the transition from speculative growth to capital efficiency, the advisory ecosystem has shifted from generalist investment institutions toward highly specialised, domain-focused boutiques. Central to this advisory transition in the European and transatlantic markets is Paul Hemings, an experienced dealmaker, entrepreneur, and Co-Founder and Partner of Nelson Advisors LLP.

Operating out of London, Nelson Advisors is a boutique corporate finance advisory firm specialising exclusively in lower-to-middle market transactions, typically targeting companies with Enterprise Values (EV) between $25 million and $250 million. Hemings brings a unique dual background to the firm: over a decade of institutional investment banking and capital markets execution at major global firms, paired with ten years of operational experience as a two-time venture founder.

During his institutional investment banking tenure, he participated in the advisory and execution of over $50 billion to $60 billion in completed M&A transactions and $40 billion to $50 billion in equity and capital markets financings across heavily regulated global sectors. As an operational founder, Hemings built and exited two ventures across metabolic health technology and consumer retail, acquiring direct experience in scaling technology, navigating regulatory hurdles, and managing corporate exits.

At Nelson Advisors LLP, co-founded alongside veteran digital health entrepreneur Lloyd Price, Hemings advises healthcare technology platforms, strategic corporate acquirers, and private equity sponsors on buy-side and sell-side M&A, corporate divestitures, roll-up strategies, and strategic growth partnerships across the United Kingdom, Europe, and North America. Hemings also serves as a Partner at VSP Investments, holds non-executive director (NED) and board advisory roles across early-stage technology companies, and acts as a corporate finance instructor and guest lecturer at institutions including London Business School.

Career Pillar	Primary Organisations & Roles	Operational & Transactional Scope	Primary Focus Areas
Institutional Corporate Finance	Senior Investment Banking Advisory, Credit Suisse (London & New York); Analyst, Invesco (Canada & UK)	$50B–$60B+ in executed M&A transactions; $40B–$50B+ in equity and capital market financings	Cross-border M&A, capital structure optimization, regulated market capital raises
Entrepreneurial Leadership	Founder & CEO, Neutrally Health; Founder & CEO, Bird Restaurants	10 years of operational founding experience; 2 successful exits (acquired by RioLife and Crown Partnership)	Metabolic HealthTech, chronic disease management platforms, multi-unit consumer retail
M&A Advisory Partnership	Co-Founder & Partner, Nelson Advisors LLP (London)	Lower-to-middle market ($25M–$250M EV); 6-to-9 month strategic advisory engagements	HealthTech, MedTech, Healthcare AI, Cybersecurity, Digital Health, TechBio
Private Equity & Governance	Partner, Investments, VSP Investments; NED & Board Advisor	Transaction entry, capital structure optimization, exit structuring, board governance	Early-stage and mid-market HealthTech, MedTech, FinTech, Consumer Tech
Academic Instruction	Finance Instructor & Guest Lecturer (LBS, Oxford, Cambridge, UCL)	Institutional corporate finance teaching, post-graduate MBA mentoring, executive finance modules	Valuation dynamics, transaction structuring, healthcare innovation financing

Institutional Corporate Finance Pedigree and Capital Markets Execution

Hemings built his corporate finance foundation through analytical and strategic roles at Invesco across its Canadian and UK operations. This early experience involved evaluating corporate strategy, asset quality, and market trends across global investment portfolios.

He subsequently transitioned into senior investment banking advisory roles at Credit Suisse, operating from the firm's financial centers in London and New York. At Credit Suisse, Hemings structured and executed cross-border M&A and corporate financing transactions for corporate clients, private equity firms, and institutional investors operating in heavily regulated sectors. His deal sheet at Credit Suisse exceeds $50 billion to $60 billion in buy-side and sell-side M&A transactions, alongside more than $40 billion to $50 billion in equity capital market financings and debt issuances. His cross-border transaction experience spans numerous international jurisdictions, including the United States, the United Kingdom, Ireland, Switzerland, Germany, Austria, Italy, Sweden, Denmark, Poland, Ukraine, Russia, Kazakhstan, Hong Kong, Singapore, and Australia.

This background provided Hemings with expertise in global capital markets, valuation methodologies, financial engineering, and complex deal mechanics. His institutional background allows him to evaluate target companies through the analytical lens of multinational healthcare strategics and private equity sponsors. He gained direct experience in capital structure optimization, equity story preparation, debt-versus-equity balancing, and initial public offering (IPO) readiness. However, while traditional investment banking focuses heavily on top-line scale and financial engineering, Hemings recognised that early-to-mid-stage technology ventures require operational insight that pure financial modelling cannot capture.

Entrepreneurial Operations and Venture Exits

Following his tenure in institutional investment banking, Hemings spent a decade as an operational founder, building and scaling ventures from inception to exit. This ten-year entrepreneurial period gave him direct exposure to product development, go-to-market strategies, unit economics, regulatory compliance, and managing cash burn.

Hemings served as Founder and CEO of Neutrally Health, a digital health platform focused on metabolic health and chronic lifestyle disease management. Neutrally developed personalized metabolic interventions by combining software, behavioral science algorithms, and remote patient monitoring. Leading Neutrally required managing software engineering teams, proving clinical utility, addressing health data privacy laws, and building subscription revenue models. Neutrally Health was ultimately acquired by RioLife, completing Hemings' first venture exit.

These founder experiences fundamentally reshaped Hemings' approach to financial advisory. Having scaled companies directly, he developed first-hand insight into the operational, structural, and psychological challenges that founders face when negotiating with institutional buyers. This combined experience as both banker and founder led to his return to corporate finance as a specialist M&A advisor.

Nelson Advisors LLP: Firm Positioning and Operational Scope

Recognising the need for domain-specific corporate finance advice in the technology sector, Paul Hemings co-founded Nelson Advisors LLP alongside Lloyd Price. Price is a digital health entrepreneur who previously co-founded Zesty, a digital patient engagement platform that grew within the UK National Health Service (NHS) before being acquired by FTSE-listed Induction Healthcare Group PLC. Operating from Hale House at 76-78 Portland Place in Marylebone, London, Nelson Advisors established itself as an advisory boutique focused strictly on the healthcare technology market.

Nelson Advisors focuses on lower-to-middle market transactions, targeting companies with Enterprise Values between $25 million and $250 million. By focusing exclusively on healthcare technology sub-sectors, the firm avoids the generalist approach of larger investment banks, developing specialised vertical expertise and regulatory knowledge instead.

The advisory services provided by Nelson Advisors span the entire transaction lifecycle for scale-up platforms, corporate divisions, and institutional investors. In sell-side M&A engagements, the firm prepares founder-led businesses for acquisition, refines their financial narratives, manages auction processes, and structures transaction terms. On the buy-side, the firm assists corporate acquirers and private equity funds in identifying, evaluating, valuing, and executing acquisitions of target platforms. The firm also advises multinational healthcare conglomerates on corporate divestitures and carve-outs, unbundling non-core software or diagnostic assets. Furthermore, Nelson Advisors designs roll-up strategies for private equity platforms consolidating fragmented markets, and structures joint ventures and strategic commercial partnerships when an outright sale is premature.

To distinguish the firm from other financial or legal entities using similar corporate names, Nelson Advisors maintains a distinct market positioning:

Organisation Name	Core Specialisation & Domain	Primary Advisory Scope	Target Client Base
Nelson Advisors LLP	Healthcare Technology M&A Advisory	M&A buy-side/sell-side, divestitures, roll-up strategies, strategic partnerships	Lower-to-mid market HealthTech, MedTech, and AI companies ($25M–$250M EV)
Nelson Capital Advisors	Fixed Income & Investment Advisory	Balance sheet advisory, fixed income portfolio management, consulting	Community financial institutions, credit unions, regional banks
Nelson Business Financial	Financial Analysis & Due Diligence	Quality of Earnings (QoE) assessments, due diligence support, turnarounds	Corporate turnaround managers, private equity diligence teams, lenders

Nelson Advisors focuses on several high-growth verticals within the healthcare landscape:

Digital Health and Consumer HealthTech: Patient engagement tools, remote monitoring devices, and metabolic health management systems.
Health IT and Clinical Workflow Platforms: Enterprise Electronic Health Record (EHR) integration, secondary care workflow orchestration, and workforce optimisation platforms.
Healthcare AI and Decision Support: Operational and clinical AI models, ambient voice technology, and diagnostic support algorithms.
Healthcare and Medical Device Cybersecurity: Software security frameworks protecting connected medical infrastructure and patient data.
TechBio and Longevity: Software platforms supporting computational biology, drug discovery, and advanced clinical research.

This vertical focus enables the firm to navigate complex regulatory requirements, including the European Union's Medical Device Regulation (EU MDR), In Vitro Diagnostic Regulation (IVDR), General Data Protection Regulation (GDPR), and the Health Insurance Portability and Accountability Act (HIPAA) in North America. This regulatory familiarity helps protect deal values during due diligence.

The "Founder Banker" Paradigm and the "Build, Buy, Partner, Sell" Framework

The European digital health and MedTech advisory market experienced a major structural shift during the mid-2020s—a period characterised by market analysts as the "Great Rationalisation". As venture subsidies decreased and capital costs rose, public markets and institutional buyers demanded clear pathways to profitability over unmonetized growth. Traditional bulge-bracket investment banks often faced challenges when valuing mid-market technology platforms whose core value rested in proprietary algorithms, clinical workflow integrations, or specialised regulatory clearances rather than established EBITDA metrics.

This shift accelerated the emergence of the "Founder Banker", a professional profile demonstrated by Hemings and Price at Nelson Advisors. Unlike traditional corporate finance advisors who progress through a standard institutional hierarchy, Founder Bankers follow a non-linear path from operational entrepreneur to successful exit, and subsequently to M&A advisor. This operational background allows them to bridge valuation gaps between agile technology founders and risk-averse institutional acquirers.

Advisory Dimension	Traditional Investment Banker	Founder Banker (Specialist Boutique Model)
Career Trajectory	Linear progression (Analyst $\rightarrow$Associate $\rightarrow$ VP $\rightarrow$MD)	Non-linear progression (Founder $\rightarrow$Scale-up $\rightarrow$ Exit $\rightarrow$ M&A Advisor)
Core Value Proposition	Financial engineering, broad distribution network, capital markets access	Operational empathy, technical fluency, founder alignment, regulatory moats
Advisory Style	Transactional, volume-driven, brand-prestige oriented	Relationship-driven, consultative, "Founders for Founders" alignment
Diligence Perspective	Historical revenue growth rates, generic EV/EBITDA multiples, TAM	Clinical utility, regulatory resilience (EU MDR/HIPAA), unit economics
Domain Expertise	Generalist coverage across broad industry categories	Deep vertical specialization (e.g., Healthcare AI, TechBio, MedTech)
Engagement Model	Short execution-focused transaction windows	6-to-9 month comprehensive corporate development partnerships

A key component of Nelson Advisors' consulting model is its "Build, Buy, Partner, Sell" strategic framework. Rather than treating M&A as a isolated transaction, Hemings and his team operate as long-term corporate development partners. Client engagements typically extend over a 6 to 9 month preparation period prior to market entry, ensuring that operational, clinical, regulatory, and financial structures are aligned before approaching buyers.

Under the "Build, Buy, Partner, Sell" framework, the firm works with client boards to evaluate the optimal path to value creation. Through the "Build" evaluation, the firm assesses whether internal R&D and organic commercial execution offer the highest risk-adjusted return on capital, or if capital constraints require an external transaction. Under the "Buy" strategy, the firm identifies targeted acquisitions to fill product gaps, obtain proprietary datasets, or expand into new geographic markets. Through "Partner" initiatives, the firm structures strategic commercial alliances, joint ventures, and distribution agreements with major corporates to establish commercial traction before executing a sale. Finally, under the "Sell" execution, the firm structures competitive sell-side M&A processes when market timing, commercial momentum, and buyer appetite align.

This consultative process helps prevent common transaction failures, such as valuation write-downs caused by unverified software code, unvalidated clinical claims, or unmitigated compliance risks under EU MDR or HIPAA rules.

Market Dynamics, Transaction Architecture and Sector Insights

Hemings' advisory perspective is informed by recurring structural shifts across global healthcare markets. His transactional commentary and industry contributions highlight key market dynamics currently shaping European and transatlantic M&A execution:

The Healthcare AI Valuation Premium versus Deployment Gap

Artificial intelligence has become a central catalyst for European and North American healthcare deal activity. Market commentary from Hemings highlights that while AI-focused startups captured approximately 65% of total healthcare equity funding in early 2025, only 40% of global healthcare startups had actively deployed operational, clinically validated AI models into live workflow environments. This creates a clear valuation divergence. Strategic acquirers offer valuation premiums—the "AI Premium"—for platforms that feature proprietary algorithms, clean clinical datasets, and direct workflow integrations. Conversely, assets with superficial AI claims face valuation reductions or failed due diligence processes.

The Transition to "String of Pearls" Acquisition Strategies

Major multinational strategic acquirers—such as Medtronic, Johnson & Johnson MedTech, and Philips—have shifted their M&A playbooks away from large-scale integrations toward structured "string of pearls" strategies. Rather than executing single multi-billion-dollar deals that carry elevated regulatory and integration risks, strategic buyers execute a series of smaller, highly targeted acquisitions to acquire specific technologies. A clear example of this approach is Johnson & Johnson MedTech's acquisition sequence, including Abiomed (2022), Laminar (2023), Shockwave Medical (2024), and V-Wave (2024). Hemings identifies this trend as a major driver for mid-market scale-ups within the $25 million to $250 million Enterprise Value range.

Private Equity Capital Allocation to Workflow Orchestration

Private equity sponsors (including specialised mid-market healthcare investors like Gilde Healthcare and Apposite Capital, alongside broader private equity funds such as TPG) are adjusting their buy-and-build models. Rather than focusing solely on direct diagnostic tools or physical facilities, private equity capital is flowing toward software-as-a-service (SaaS) workflow orchestration, administrative automation, and workforce optimization platforms. Transactions such as T-Pro's acquisition of BigHand Healthcare and TPG's strategic positioning in primary care IT through EMIS illustrate a market-wide emphasis on software that reduces administrative overhead and alleviates clinical burnout.

Transaction Complexity in "TechBio" and Longevity

Hemings focuses significantly on the "TechBio" and longevity verticals, sectors where advanced computational models interface with complex biological research. These fields feature high capital requirements, dense scientific concepts, and extended development timelines. Executing M&A transactions in TechBio requires specialized deal structures, such as structured earn-outs linked to clinical milestones, contingent value rights (CVRs), and strategic joint ventures that mitigate risk for acquirers while preserving upside for early shareholders.

Governance, Investment Advisory and Academic Contributions

In addition to his advisory duties at Nelson Advisors LLP, Paul Hemings maintains active roles across institutional investment execution, board governance, and academic instruction.

Educational Credentials

Hemings earned a Bachelor of Arts (Honours) in Economics from Queen's University in Canada, establishing his foundation in econometric modeling, quantitative analysis, and macroeconomics. He later completed his Master of Business Administration (MBA) at London Business School (LBS), focusing on corporate finance, private equity, and advanced transaction structuring.

Private Equity and Investment Execution at VSP Investments

As a Partner at VSP Investments, Hemings applies his corporate finance background directly to growth capital investments and asset governance. His responsibilities within the firm cover the full investment lifecycle:

Transaction Entry and Deal Structuring: Leading investment execution, evaluating entry valuations, negotiating shareholder rights, and structuring investment terms.
Capital Structure Optimisation: Designing efficient debt-and-equity capital structures that maximise operational flexibility and capital efficiency.
Exit Structuring and Execution: Preparing portfolio assets for liquidity events, evaluating M&A trade sales versus initial public offerings, and executing exit processes to maximise investor returns.
Board Leadership and Governance: Serving in board advisory and non-executive director (NED) roles across technology scale-ups in the HealthTech, MedTech, FinTech, and consumer sectors.

Institutional Teaching and Academic Mentorship

Hemings regularly serves as a corporate finance instructor and guest lecturer across business schools and universities in the United Kingdom and Europe. His academic work focuses on teaching advanced corporate finance, valuation techniques, M&A deal dynamics, and venture financing to post-graduate MBA candidates, MSc students, and corporate executives.

His primary academic engagements include:

London Business School (LBS): Lecturing on applied corporate finance, M&A deal structuring, and venture exit strategies.
University College London (UCL) Global Business School for Health: Contributing to specialised modules examining healthcare innovation finance, digital health economics, and strategic M&A within global healthcare systems.

Through these teaching commitments, Hemings helps educate future entrepreneurs, corporate development executives, and healthcare investors, bridging theoretical academic models with practical M&A execution.

Strategic Conclusions

The career of Paul Hemings and the strategic growth of Nelson Advisors LLP reflect broader developments within the middle-market corporate finance ecosystem. As healthcare technology sub-sectors become increasingly complex, the market value of generalist investment advisory models has declined in favour of specialised, domain-focused boutiques.

By combining institutional corporate finance experience from Credit Suisse with a decade of operational startup leadership, Hemings demonstrates the "Founder Banker" model. His work at Nelson Advisors LLP addresses a clear market need in the $25 million to $250 million Enterprise Value segment, providing mid-market healthcare technology founders and investors with corporate finance execution grounded in real-world operational insight.

As healthcare systems continue to adopt artificial intelligence, software workflow orchestration, and computational biology platforms, the demand for advisors who understand both clinical technology and complex capital structures will remain strong. Through Nelson Advisors' "Build, Buy, Partner, Sell" framework, Hemings remains actively involved in shaping healthcare technology M&A and corporate development across European and transatlantic markets.

Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #MedTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech #ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #Canada #Commonwealth #CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics